{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:14:10Z","timestamp":1780470850460,"version":"3.54.1"},"reference-count":21,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"abstract":"<jats:p>&lt;p&gt;Introduction: Recent advances in genomic research have expanded the treatment landscape for acute myeloid leukemia (AML). This study examined treatment patterns and clinical outcomes among relapsed\/refractory (R\/R) FMS-like tyrosine kinase 3 (FLT3)-mutated AML patients. Methods: This retrospective longitudinal study included patients with confirmed AML diagnosis, FLT3 mutation, and 1st R\/R event from 1\/1\/2015 to 1\/31\/2023 in the ConcertAI Oncology Dataset. Treatment patterns, FLT3 testing rates, real-world overall survival (rwOS), and real-world time to next treatment (rwTTNT) were studied. Results: Among the 336 treated patients, 50.6% received FLT3-tyrosine kinase inhibitors (FLT3-TKIs) as first treatment after R\/R event, of which 51.8% received gilteritinib. High-intensity chemotherapy used as first treatment after R\/R event decreased from 67.9% in 2015 to 20.0% in 2022, while FLT3-TKI utilization rose to 50% over the same period. Among the 246 patients tested for FLT3 at initial AML diagnosis, only 36% were retested at 1st R\/R event. Median rwOS and rwTTNT among FLT3-TKI patients were 12.4 months and 2.9 months, respectively. Conclusion: This study reveals a trend toward increasing FLT3-TKI use and highlights the need for repeated FLT3 testing among R\/R AML patients. Real-world evidence is vital in understanding R\/R AML patient care amidst emerging therapies. &lt;\/p&gt;<\/jats:p>","DOI":"10.1159\/000545384","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T12:00:38Z","timestamp":1744632038000},"page":"125-136","source":"Crossref","is-referenced-by-count":2,"title":["Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia \u2013 Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis"],"prefix":"10.1159","volume":"149","author":[{"given":"Amer M.","family":"Zeidan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Grinblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Elsouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Spalding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maelys","family":"Touya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavik J.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0170-3"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000572"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113225"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0357-9"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225722"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.6.1752"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112304"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-782292"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01148-x"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6442"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.09.701"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.16"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1399312"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13205"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100016"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199701"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26447"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150169"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0876"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106353"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/aha\/article-pdf\/doi\/10.1159\/000545384\/4365120\/000545384.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000545384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:01:20Z","timestamp":1774285280000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000545384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,23]]},"published-print":{"date-parts":[[2026,3,26]]}},"URL":"https:\/\/doi.org\/10.1159\/000545384","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.28786382","asserted-by":"subject"}]},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"value":"0001-5792","type":"print"},{"value":"1421-9662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]}}}